InnoSlim® is a pharmaceutical-grade glucose and lipid metabolic regulator through activation of the adiponectin and AMPK signaling pathway
MECHANISM OF ACTION
- Supports healthy blood sugar levels in studied human subjects*
- Promotes healthy lipid and cholesterol levels in studied human subjects*
INNOSLIM® SUPPORTS HEALTHY GLUCOSE LEVELS
IN HUMAN SUBJECTS
Adiponectin mRNA (%)
Plasma Adiponectin (%)
Plasma AMPK (%)
Fasting Blood Glucose (%)
HOW INNOSLIM® WORKS
InnoSlim® has demonstrated in NuLiv Science in-vitro, in-vivo, and human studies to have promising effects on reducing fasting glucose levels and improving metabolic function in tested subjects. These studies suggest that InnoSlim® could achieve this by activating a specific pathway called the adiponectin and AMPK signaling pathway, which plays a role in regulating the levels of fats and sugar in the bloodstream.
Decreased levels of adiponectin are linked to difficulties in regulating blood sugar and breaking down fatty acids. Adiponectin functions by controlling the cellular energy metabolism through the regulation of the AMPK signaling pathway. When adiponectin levels increase, there is a subsequent rise in AMPK phosphorylation, which promotes the breakdown of fatty acids. Additionally, AMPK enhances the regulation of a glucose transporter called GLUT4 in muscle and fat tissues, leading to increased glucose uptake and improved metabolic function.
By increasing adiponectin levels and secretion in fat cells, InnoSlim® works to stimulate the phosphorylation and activation of AMPK in skeletal muscles. This activation is followed by the activation of GLUT4 and increased phosphorylation of ACC, resulting in the breakdown of fatty acids and uptake of glucose in muscle cells. These effects have been observed in in-vitro and in-vivo studies conducted by NuLiv Science.1, 2, 3 Moreover, human clinical trials have further supported these findings by demonstrating that InnoSlim® may enhance the adiponectin and AMPK signaling pathway in tested subjects, leading to potential improvements in blood sugar and lipid levels.4, 5
Highly purified fractions extracted from NLF-03 Astragalus membranaceus (root)
and Panax notoginseng (root).
Clinical Dosage: 250mg
1. Y.C. Huang, etc. Effect and mechanism of ginsenosides CK and Rg1 on stimulation of glucose uptake in 3T3-L1 adipocytes. Journal of Agricultural Food Chemistry. 2010, 58, 6039–6047.
2. W.L. Chang, etc. The inhibitory effect of ginsenoside Rg1 on glucose and lipid production in human HepG2 cells. Adaptive Medicine. 2013, 5(4):181-188.
3. C.W. Wang, etc. An essential role of cAMP response element binding protein in ginsenoside Rg1-mediated inhibition of Na1/glucose cotransporter 1 gene expression. Molecular Pharmacology.2015, 88(6):1072-83.
4. S.C. Huang, etc. Radix Astragali and Notoginseng saponins improve glucose and fatty acid metabolism through upregulated adiponectin and its downstream signaling. J of Biochemistry and Biotechnology, August 2021.
5. S.C. Huang, etc. Anti-hyperglycemic and anti-hyperlipidemic activities of Radix Astragali and Panax notoginseng extract in human participants: A randomized, double-blind, crossover clinical trial. J. of Biochemistry and Biotechnology, June 2022.
*These statements may not comply with your country’s laws and regulations or with Reg. EC n. 1924/2006 and have not been evaluated by the Food and Drug Administration. The products are not intended to diagnose, treat, cure or prevent any disease. Marketers of finished products containing this ingredient are responsible for ensuring compliance with the applicable legal framework.